You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 150 No. 9, September 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  REVIEW ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure

Prakash C. Deedwania, MD

Arch Intern Med. 1990;150(9):1798-1805.


Abstract

• Angiotensin-converting enzyme inhibitors have had a significant impact on the treatment of congestive heart failure (CHF). Hemodynamic and clinical improvements in patients with severe CHF fostered the use of angiotensin-converting enzyme inhibitors in mild to moderate CHF. Angiotensin-converting enzyme inhibitors produce acute and sustained improvements in ventricular hemodynamics and quality of life. Captopril plus diuretic therapy is an effective alternative to digoxin in patients with mild to moderate CHF. Enalapril meleate and lisinopril have been shown to be effective in moderate to severe CHF when combined with digoxin and diuretics. Captopril and enalapril also improve survival in selected patients; captopril attenuates left ventricular dilatation after myocardial infarction. Although all angiotensinconverting enzyme inhibitors are similar in mechanism of action, pharmacokinetic differences impact their clinical use. Prolonged symptomatic hypotension compromising systemic perfusion and organ function has been reported with longer-acting agents; hypotension is usually short-lived and rarely compromises organ function with shorter-acting agents.

(Arch Intern Med. 1990;150:1798-1805)



Author Affiliations

From the Cardiology Section, Veterans Administration Medical Center, Fresno, Calif.


Footnotes

Accepted for publication February 14,1990.

Reprint requests to Cardiology Section, Veterans Administration Medical Center, 2615 E Clinton Ave, Fresno, CA 93703 (Dr Deedwania).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improving Treatment Effectiveness in Hypertension
Freis
Arch Intern Med 1999;159:2517-2521.
FULL TEXT  

Underutilization of Evidence-Based Therapy in Heart Failure: An Opportunity to Deal a Winning Hand With Ace up Your Sleeve
Deedwania
Arch Intern Med 1997;157:2409-2412.
ABSTRACT  

Angiotensin-Converting Enzyme Inhibitors (ACE) in Congestive Heart Failure-Reply
Deedwania
Arch Intern Med 1991;151:1670-1670.
ABSTRACT  

Angiotensin-Converting Enzyme Inhibitors (ACE) in Congestive Heart Failure
Fukuyama
Arch Intern Med 1991;151:1669-1670.
ABSTRACT  

All ACE Inhibitors Are Not Alike
Cheng
Arch Intern Med 1991;151:1670-1670.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.